Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1133-1144

  Risacher, Shannon L ^a   WuDunn, Darrell ^a   Pepin, Susan M ^b   MaGee, Tamiko R ^a   McDonald, Brenna C ^a,b   Flashman, Laura A ^b   Wishart, Heather A ^b   Pixley, Heather S ^b   Rabin, Laura A ^b,c   Paré, Nadia ^b,d   Englert, Jessica J ^b   Schwartz, Eben ^b   Curtain, Joshua R ^b   West, John D ^a   O'Neill, Darren P ^a   Santulli, Robert B ^b   Newman, Richard W ^e,f   Saykin, Andrew J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

^e Center for Science and Technology   (United States)

^f Cornell University   (United States)

Author keywords

Alzheimer's disease (AD); Biomarker; Cognitive complaints; Contrast sensitivity (CS); Frequency doubling technology (FDT); Mild cognitive impairment (MCI); Vision

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTRAST SENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VISION; VISUAL ACUITY; VISUAL FIELD; VISUAL SYSTEM FUNCTION; VISUAL SYSTEM PARAMETERS;

AGED; ALZHEIMER DISEASE; COMORBIDITY; CONTRAST SENSITIVITY; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES; VISION DISORDERS;

EID: 84872329712     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.08.007     Document Type: Article

References (84)

1. Ahmed S., Mitchell J., Arnold R., Dawson K., Nestor P.J., Hodges J.R. Memory complaints in mild cognitive impairment, worried well, and semantic dementia patients. Alzheimer Dis. Assoc. Disord. 2008, 22:227-235.
2. Al-Dabbagh N.M., Al-Dohayan N., Arfin M., Tariq M. Apolipoprotein E polymorphisms and primary glaucoma in Saudis. Mol. Vis. 2009, 15:912-919.
3. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7:208-244.
4. Anderson A.J., Johnson C.A. Frequency-doubling technology perimetry. Ophthalmol. Clin. North Am. 2003, 16:213-225.
5. Anderson A.J., Johnson C.A., Fingeret M., Keltner J.L., Spry P.G., Wall M., Werner J.S. Characteristics of the normative database for the Humphrey matrix perimeter. Invest. Ophthalmol. Vis. Sci. 2005, 46:1540-1548.
6. Armstrong R.A. Visual field defects in Alzheimer's disease patients may reflect differential pathology in the primary visual cortex. Optom. Vis. Sci. 1996, 73:677-682.
7. Bayer A.U., Ferrari F., Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur. Neurol. 2002, 47:165-168.
8. Berisha F., Feke G.T., Trempe C.L., McMeel J.W., Schepens C.L. Retinal abnormalities in early Alzheimer's disease. Invest. Ophthalmol. Vis. Sci. 2007, 48:2285-2289.
9. Blanks J.C., Hinton D.R., Sadun A.A., Miller C.A. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989, 501:364-372.
10. Blanks J.C., Schmidt S.Y., Torigoe Y., Porrello K.V., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol. Aging 1996, 17:385-395.
11. Blanks J.C., Torigoe Y., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging 1996, 17:377-384.
12. Cello K.E., Nelson-Quigg J.M., Johnson C.A. Frequency doubling technology perimetry for detection of glaucomatous visual field loss. Am. J. Ophthalmol. 2000, 129:314-322.
13. Cockrell J.R., Folstein M.F. Mini-Mental State Examination (MMSE). Psychopharmacol. Bull. 1988, 24:689-692.
14. Cronin-Golomb A. Vision in Alzheimer's disease. Gerontologist 1995, 35:370-376.
15. Cronin-Golomb A., Corkin S., Rizzo J.F., Cohen J., Growdon J.H., Banks K.S. Visual dysfunction in Alzheimer's disease: relation to normal aging. Ann. Neurol. 1991, 29:41-52.
16. Cronin-Golomb A., Rizzo J.F., Corkin S., Growdon J.H. Visual function in Alzheimer's disease and normal aging. Ann. N. Y. Acad. Sci. 1991, 640:28-35.
17. Curcio C.A., Drucker D.N. Retinal ganglion cells in Alzheimer's disease and aging. Ann. Neurol. 1993, 33:248-257.
18. Delis D., Kramer J., Kaplan E., Ober B. California Verbal Learning Test: Adult Version Research Edition Manual 1987, The Psychological Corporation, San Antonio, TX.
19. Delis D., Kramer J., Kaplan E., Ober B. California Verbal Learning Test-Second Edition: Adult Version Manual 2000, The Psychological Corporation, San Antonio, TX.
20. Dik M.G., Jonker C., Comijs H.C., Bouter L.M., Twisk J.W., van Kamp G.J., Deeg D.J. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001, 57:2217-2222.
21. Djordjevic J., Jones-Gotman M., De Sousa K., Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2008, 29:693-706.
22. Elliott D.B. Evaluating visual function in cataract. Optom. Vis. Sci. 1993, 70:896-902.
23. Elliott D.B., Gilchrist J., Whitaker D. Contrast sensitivity and glare sensitivity changes with three types of cataract morphology: are these techniques necessary in a clinical evaluation of cataract?. Ophthalmic Physiol. Opt. 1989, 9:25-30.
24. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
25. Frost S., Martins R.N., Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's disease. J. Alzheimers Dis. 2010, 22:1-16.
26. Gilmore G.C., Morrison S., Groth K. Magnocellular deficit hypothesis in Alzheimer's disease. Interdisciplinary Topics in Gerontology: Vision in Alzheimer's Disease and Related Disorders 2004, 173-198. Karger, Basel. A. Cronin-Golomb, P.R. Hof (Eds.).
27. Gilmore G.C., Wenk H.E., Naylor L.A., Koss E. Motion perception and Alzheimer's disease. J. Gerontol. 1994, 49:P52-P57.
28. Gilmore G.C., Whitehouse P.J. Contrast sensitivity in Alzheimer's disease: a 1-year longitudinal analysis. Optom. Vis. Sci. 1995, 72:83-91.
29. Goldstein L.E., Muffat J.A., Cherny R.A., Moir R.D., Ericsson M.H., Huang X., Mavros C., Coccia J.A., Faget K.Y., Fitch K.A., Masters C.L., Tanzi R.E., Chylack L.T., Bush A.I. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 2003, 361:1258-1265.
30. Guo L., Duggan J., Cordeiro M.F. Alzheimer's disease and retinal neurodegeneration. Curr. Alzheimer Res. 2010, 7:3-14.
31. Guo L., Salt T.E., Luong V., Wood N., Cheung W., Maass A., Ferrari G., Russo-Marie F., Sillito A.M., Cheetham M.E., Moss S.E., Fitzke F.W., Cordeiro M.F. Targeting amyloid-beta in glaucoma treatment. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13444-13449.
32. Heaton R., Chelune G., Talley J., Kay G., Curtis G. Wisconsin Card Sorting Test Manual Revised and Expanded 1993, Psychological Assessment Resources, Odessa, FL.
33. Hinton D.R., Sadun A.A., Blanks J.C., Miller C.A. Optic-nerve degeneration in Alzheimer's disease. N. Engl. J. Med. 1986, 315:485-487.
34. Hof P.R., Morrison J.H. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J. Comp. Neurol. 1990, 301:55-64.
35. Idrizbegovic E., Hederstierna C., Dahlquist M., Kampfe Nordstrom C., Jelic V., Rosenhall U. Central auditory function in early Alzheimer's disease and in mild cognitive impairment. Age Ageing 2011, 40:249-254.
36. Iester M., Capris P., Pandolfo A., Zingirian M., Traverso C.E. Learning effect, short-term fluctuation, and long-term fluctuation in frequency doubling technique. Am. J. Ophthalmol. 2000, 130:160-164.
37. Iliadou V., Kaprinis S. Clinical psychoacoustics in Alzheimer's disease central auditory processing disorders and speech deterioration. Ann. Gen. Hosp. Psychiatry 2003, 2:12.
38. Iseri P.K., Altinas O., Tokay T., Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 2006, 26:18-24.
39. Jackson G.R., Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol. Clin. 2003, 21:709-728.
40. Janciauskiene S., Krakau T. Alzheimer's peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer's disease. Acta Ophthalmol. Scand. 2001, 79:328-329.
41. Johnson C.A., Samuels S.J. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest. Ophthalmol. Vis. Sci. 1997, 38:413-425.
42. Jurica P., Leitten C., Mattis S. Dementia Rating Scale - 2 2001, Psychological Assessment Resources, Inc, Lutz, FL.
43. Katz B., Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv. Ophthalmol. 1989, 34:31-43.
44. Katz B., Rimmer S., Iragui V., Katzman R. Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration?. Ann. Neurol. 1989, 26:221-225.
45. Kelly D.H. Nonlinear visual responses to flickering sinusoidal gratings. J. Opt. Soc. Am. 1981, 71:1051-1055.
46. Kergoat H., Kergoat M.J., Justino L., Chertkow H., Robillard A., Bergman H. An evaluation of the retinal nerve fiber layer thickness by scanning laser polarimetry in individuals with dementia of the Alzheimer type. Acta Ophthalmol. Scand. 2001, 79:187-191.
47. Koronyo-Hamaoui M., Koronyo Y., Ljubimov A.V., Miller C.A., Ko M.K., Black K.L., Schwartz M., Farkas D.L. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011, 54:S204-S217.
48. Koronyo Y., Salumbides B.C., Black K.L., Koronyo-Hamaoui M. Alzheimer's disease in the retina: imaging retinal aβ plaques for early diagnosis and therapy assessment. Neurodegener. Dis. 2012, 10:1-9.
49. Leuba G., Saini K. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 1995, 21:410-422.
50. Mabuchi F., Tang S., Ando D., Yamakita M., Wang J., Kashiwagi K., Yamagata Z., Iijima H., Tsukahara S. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mol. Vis. 2005, 11:609-612.
51. Martinelli V., Locatelli T., Comi G., Lia C., Alberoni M., Bressi S., Rovaris M., Franceschi M., Canal N. Pattern visual evoked potential mapping in Alzheimer's disease: correlations with visuospatial impairment. Dementia 1996, 7:63-68.
52. McKee A.C., Au R., Cabral H.J., Kowall N.W., Seshadri S., Kubilus C.A., Drake J., Wolf P.A. Visual association pathology in preclinical Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65:621-630.
53. McKendrick A.M., Turpin A. Advantages of terminating Zippy Estimation by Sequential Testing (ZEST) with dynamic criteria for white-on-white perimetry. Optom. Vis. Sci. 2005, 82:981-987.
54. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
55. Mielke R., Kessler J., Fink G., Herholz K., Heiss W.D. Dysfunction of visual cortex contributes to disturbed processing of visual information in Alzheimer's disease. Int. J. Neurosci. 1995, 82:1-9.
56. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
57. Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19067-19072.
58. Neargarder S.A., Stone E.R., Cronin-Golomb A., Oross S. The impact of acuity on performance of four clinical measures of contrast sensitivity in Alzheimer's disease. J. Gerontol. B Psychol. Sci. Soc. Sci. 2003, 58:P54-P62.
59. Pache M., Smeets C.H., Gasio P.F., Savaskan E., Flammer J., Wirz-Justice A., Kaiser H.J. Colour vision deficiencies in Alzheimer's disease. Age Ageing 2003, 32:422-426.
60. Paquet C., Boissonnot M., Roger F., Dighiero P., Gil R., Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2007, 420:97-99.
61. Parisi V., Restuccia R., Fattapposta F., Mina C., Bucci M.G., Pierelli F. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin. Neurophysiol. 2001, 112:1860-1867.
62. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
63. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
64. Richards W., Felton T.B. Spatial frequency doubling: retinal or central?. Vision Res. 1973, 13:2129-2137.
65. Sadun A.A. The optic neuropathy of Alzheimer's disease. Metab. Pediatr. Syst. Ophthalmol. 1989, 12:64-68.
66. Sadun A.A., Bassi C.J. Optic nerve damage in Alzheimer's disease. Ophthalmology 1990, 97:9-17.
67. Saykin A.J., Wishart H.A., Rabin L.A., Santulli R.B., Flashman L.A., West J.D., McHugh T.L., Mamourian A.C. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006, 67:834-842.
68. Scarmeas N., Stern Y. Imaging studies and APOE genotype in persons at risk for Alzheimer's disease. Curr. Psychiatry Rep. 2006, 8:11-17.
69. Schiffman S.S. Taste and smell losses in normal aging and disease. JAMA 1997, 278:1357-1362.
70. Smith C.D., Andersen A.H., Kryscio R.J., Schmitt F.A., Kindy M.S., Blonder L.X., Avison M.J. Women at risk for AD show increased parietal activation during a fluency task. Neurology 2002, 58:1197-1202.
71. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
72. Sponsel W.E., Trigo Y., Hendricks J., Lloyd C. Frequency doubling perimetry. Am. J. Ophthalmol. 1998, 126:155-156.
73. Tamura H., Kawakami H., Kanamoto T., Kato T., Yokoyama T., Sasaki K., Izumi Y., Matsumoto M., Mishima H.K. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J. Neurol. Sci. 2006, 246:79-83.
74. Tatemichi M., Nakano T., Tanaka K., Hayashi T., Nawa T., Miyamoto T., Hiro H., Iwasaki A., Sugita M. Performance of glaucoma mass screening with only a visual field test using frequency-doubling technology perimetry. Am. J. Ophthalmol. 2002, 134:529-537.
75. Tsai C.S., Ritch R., Schwartz B., Lee S.S., Miller N.R., Chi T., Hsieh F.Y. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch. Ophthalmol. 1991, 109:199-204.
76. Turpin A., McKendrick A.M., Johnson C.A., Vingrys A.J. Properties of perimetric threshold estimates from full threshold, ZEST, and SITA-like strategies, as determined by computer simulation. Invest. Ophthalmol. Vis. Sci. 2003, 44:4787-4795.
77. Valenti D.A. Neuroimaging of retinal nerve fiber layer in AD using optical coherence tomography. Neurology 2007, 69:1060.
78. Valenti D.A. Alzheimer's disease: visual system review. Optometry 2010, 81:12-21.
79. Vickers J.C., Craig J.E., Stankovich J., McCormack G.H., West A.K., Dickinson J.L., McCartney P.J., Coote M.A., Healey D.L., Mackey D.A. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol. Vis. 2002, 8:389-393.
80. White A.J., Sun H., Swanson W.H., Lee B.B. An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest. Ophthalmol. Vis. Sci. 2002, 43:3590-3599.
81. Wostyn P., Audenaert K., De Deyn P.P. Alzheimer's disease and glaucoma: is there a causal relationship?. Br. J. Ophthalmol. 2009, 93:1557-1559.
82. Yin H., Chen L., Chen X., Liu X. Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med. Hypotheses 2008, 71:77-80.
83. Yoneda S., Hara H., Hirata A., Fukushima M., Inomata Y., Tanihara H. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn. J. Ophthalmol. 2005, 49:106-108.
84. Zeppieri, M., Johnson, C.A., 2008. Frequency Doubling Techology (FDT) Perimetry. Available at: http://webeye.ophth.uiowa.edu/ips/perimetryhistory/FDP/index.htm.